Bank Julius Baer & Co. Ltd Zurich Grows Position in Moderna, Inc. (NASDAQ:MRNA)

Bank Julius Baer & Co. Ltd Zurich raised its position in Moderna, Inc. (NASDAQ:MRNA) by 52.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 202,524 shares of the company’s stock after purchasing an additional 69,441 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Moderna were worth $20,141,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. First Pacific Financial purchased a new position in shares of Moderna in the 3rd quarter worth about $27,000. Arlington Trust Co LLC grew its stake in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC grew its stake in shares of Moderna by 54.1% in the third quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock valued at $53,000 after buying an additional 180 shares in the last quarter. Archer Investment Corp grew its stake in shares of Moderna by 71.2% in the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after buying an additional 222 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its stake in shares of Moderna by 44.9% in the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after buying an additional 175 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now owns 8,557 shares in the company, valued at $809,235.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the completion of the transaction, the president now owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Shannon Thyme Klinger sold 670 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $63,361.90. Following the transaction, the insider now directly owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The disclosure for this sale can be found here. Insiders have sold 109,954 shares of company stock worth $11,533,976 in the last three months. 15.70% of the stock is currently owned by insiders.

Moderna Price Performance

Shares of MRNA stock traded up $1.79 during mid-day trading on Friday, hitting $107.97. 2,245,667 shares of the stock traded hands, compared to its average volume of 4,077,747. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $142.79. The firm has a market cap of $41.34 billion, a price-to-earnings ratio of -8.70 and a beta of 1.62. The company’s 50-day simple moving average is $102.15 and its 200-day simple moving average is $93.73. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company’s quarterly revenue was down 44.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.61 EPS. As a group, equities research analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current year.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of recent analyst reports. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a research note on Tuesday, January 2nd. HSBC reiterated a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Royal Bank of Canada reiterated an “outperform” rating and issued a $125.00 target price on shares of Moderna in a research report on Thursday, March 28th. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus price target of $126.49.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.